表紙
市場調查報告書

危急性肢體缺血:開發中產品分析

Critical Limb Ischemia - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 219779
出版日期 內容資訊 英文 143 Pages
訂單完成後即時交付
價格
Back to Top
危急性肢體缺血:開發中產品分析 Critical Limb Ischemia - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 143 Pages
簡介

所謂危急性肢體缺血是週邊動脈疾病(PAD)中最危及生命的症狀。一般是由於動脈粥狀硬化性心血管疾病相關的慢性發炎過程所造成。主要的症狀有腳·腳尖的疼痛和發麻、潰爛、皮膚感染疾病等,無論是何者在發症後都無法治療。這個疾病的治療目的在於減輕危及冠狀動脈的風險要素(禁煙、減輕膽固醇等)、減輕疼痛、治癒潰瘍、避免截肢手術、改善生活品質、提升生存率等。

本報告提供全球各國治療危急性肢體缺血(CLI)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

危急性肢體缺血 - 概要

危急性肢體缺血 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

危急性肢體缺血 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

危急性肢體缺血的開發治療藥的企業

  • AnGes MG Inc
  • apceth Biopharma GmbH
  • Athersys Inc
  • BiogenCell Ltd
  • Caladrius Biosciences Inc
  • Cynata Therapeutics Ltd
  • Hemostemix Ltd
  • Histocell SL
  • ID Pharma Co Ltd
  • Integene International Holdings LLC
  • Juventas Therapeutics Inc
  • Kasiak Research Pvt Ltd
  • Kowa Company Ltd
  • Neurofx Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • ReNeuron Group Plc
  • Symic Biomedical Inc
  • TikoMed AB
  • U.S. Stem Cell Inc
  • Vericel Corp
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd

藥物簡介

危急性肢體缺血 - 暫停中的計劃

危急性肢體缺血 - 開發中止的產品

危急性肢體缺血 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11522IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2019, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 15, 3, 1 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Critical Limb Ischemia - Overview
  • Critical Limb Ischemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Critical Limb Ischemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Critical Limb Ischemia - Companies Involved in Therapeutics Development
    • Anaeropharma Science Inc
    • Antidote Therapeutics Inc
    • apceth Biopharma GmbH
    • Athersys Inc
    • BiogenCell Ltd
    • Biotech Holdings
    • Caladrius Biosciences Inc
    • Constant Therapeutics LLC
    • Cynata Therapeutics Ltd
    • Helixmith Co Ltd
    • Hemostemix Inc
    • Histocell SL
    • ID Pharma Co Ltd
    • Integene International Holdings LLC
    • Juventas Therapeutics Inc
    • Kang Stem Biotech Co Ltd
    • Libella Gene Therapeutics
    • LifeCells LLC
    • Nissan Chemical Corp
    • Pharmicell Co Ltd
    • Pluristem Therapeutics Inc
    • ReNeuron Group Plc
    • Reven Pharmaceuticals Inc
    • Rexgenero Ltd
    • TaiGen Biotechnology Co Ltd
    • Taiwan Bio Therapeutics Co Ltd
    • Theratome Bio Inc
    • U.S. Stem Cell Inc
    • VESSL Therapeutics Ltd
    • Yichang Humanwell Pharmaceutical Co Ltd
  • Critical Limb Ischemia - Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AdipoCell - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Alecmestencel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASCT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-1013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGC-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biochymal - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • burixafor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellgram-CLI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLBS-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CYP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • donaperminogene seltoplasmid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DVC-10101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emiplacel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate FGF2 for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate TERT for Alzheimer's Disease, Ageing and Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HC-016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Multistem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pitavastatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Procell - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rejuveinix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ReN-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REX-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Thera-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Critical Limb Ischemia - Dormant Projects
  • Critical Limb Ischemia - Discontinued Products
  • Critical Limb Ischemia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Critical Limb Ischemia, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 5: Products under Development by Companies, H2 2019
  • Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 8: Products under Development by Universities/Institutes, H2 2019
  • Table 9: Number of Products by Stage and Target, H2 2019
  • Table 10: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 11: Number of Products by Stage and Route of Administration, H2 2019
  • Table 12: Number of Products by Stage and Molecule Type, H2 2019
  • Table 13: Critical Limb Ischemia - Pipeline by Anaeropharma Science Inc, H2 2019
  • Table 14: Critical Limb Ischemia - Pipeline by Antidote Therapeutics Inc, H2 2019
  • Table 15: Critical Limb Ischemia - Pipeline by apceth Biopharma GmbH, H2 2019
  • Table 16: Critical Limb Ischemia - Pipeline by Athersys Inc, H2 2019
  • Table 17: Critical Limb Ischemia - Pipeline by BiogenCell Ltd, H2 2019
  • Table 18: Critical Limb Ischemia - Pipeline by Biotech Holdings, H2 2019
  • Table 19: Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H2 2019
  • Table 20: Critical Limb Ischemia - Pipeline by Constant Therapeutics LLC, H2 2019
  • Table 21: Critical Limb Ischemia - Pipeline by Cynata Therapeutics Ltd, H2 2019
  • Table 22: Critical Limb Ischemia - Pipeline by Helixmith Co Ltd, H2 2019
  • Table 23: Critical Limb Ischemia - Pipeline by Hemostemix Inc, H2 2019
  • Table 24: Critical Limb Ischemia - Pipeline by Histocell SL, H2 2019
  • Table 25: Critical Limb Ischemia - Pipeline by ID Pharma Co Ltd, H2 2019
  • Table 26: Critical Limb Ischemia - Pipeline by Integene International Holdings LLC, H2 2019
  • Table 27: Critical Limb Ischemia - Pipeline by Juventas Therapeutics Inc, H2 2019
  • Table 28: Critical Limb Ischemia - Pipeline by Kang Stem Biotech Co Ltd, H2 2019
  • Table 29: Critical Limb Ischemia - Pipeline by Libella Gene Therapeutics, H2 2019
  • Table 30: Critical Limb Ischemia - Pipeline by LifeCells LLC, H2 2019
  • Table 31: Critical Limb Ischemia - Pipeline by Nissan Chemical Corp, H2 2019
  • Table 32: Critical Limb Ischemia - Pipeline by Pharmicell Co Ltd, H2 2019
  • Table 33: Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc, H2 2019
  • Table 34: Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H2 2019
  • Table 35: Critical Limb Ischemia - Pipeline by Reven Pharmaceuticals Inc, H2 2019
  • Table 36: Critical Limb Ischemia - Pipeline by Rexgenero Ltd, H2 2019
  • Table 37: Critical Limb Ischemia - Pipeline by TaiGen Biotechnology Co Ltd, H2 2019
  • Table 38: Critical Limb Ischemia - Pipeline by Taiwan Bio Therapeutics Co Ltd, H2 2019
  • Table 39: Critical Limb Ischemia - Pipeline by Theratome Bio Inc, H2 2019
  • Table 40: Critical Limb Ischemia - Pipeline by U.S. Stem Cell Inc, H2 2019
  • Table 41: Critical Limb Ischemia - Pipeline by VESSL Therapeutics Ltd, H2 2019
  • Table 42: Critical Limb Ischemia - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H2 2019
  • Table 43: Critical Limb Ischemia - Dormant Projects, H2 2019
  • Table 44: Critical Limb Ischemia - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Table 45: Critical Limb Ischemia - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Critical Limb Ischemia, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products by Targets, H2 2019
  • Figure 4: Number of Products by Stage and Targets, H2 2019
  • Figure 5: Number of Products by Mechanism of Actions, H2 2019
  • Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Top 10 Routes of Administration, H2 2019
  • Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Molecule Types, H2 2019
  • Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Back to Top